ArticlePatient preference and adherence2025
Association of the Driving Distance, Driving Time, and Public Transit Time to the Hospital with the Persistence of Tumor Necrosis Factor Inhibitors in Patients With Ankylosing Spondylitis: A Retrospective Cohort Study.
Article in Patient preference and adherence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Time Toxicity of Endocrine-based Oral CDK4/6 Inhibitor Therapies.Geburtshilfe und Frauenheilkunde · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Research on the impact of geographical distance from or travel time to healthcare facilities on treatment adherence among patients with rheumatic diseases is lacking. Therefore, we investigated the association of the driving distance, driving time, and public transit time to the hospital with the persistence of tumor necrosis factor-alpha (TNF-α) inhibitors in patients with ankylosing spondylitis (AS). Patients and Methods: This 19-year retrospective cohort study was performed in the rheumatology department of a tertiary hospital in Korea and analyzed 313 adult patients with AS who were newly initiated on TNF-α inhibitors. The driving distance, driving time, and public transit time to the hospital were calculated using the Naver Map application. Drug persistence of TNF-α inhibitors was defined as the time duration between the index date and the date of discontinuation without exceeding a treatment gap of 90 days. Results: The most commonly prescribed TNF-α inhibitor in patients with AS was adalimumab (69.3%), followed by etanercept (21.4%) and infliximab (9.3%). The median driving distance, driving time, and public transit time to the hospital were 16 kilometers (km), 0.6 hours, and 0.8 hours, respectively. In total, 120 (38.3%) patients with AS stopped TNF-α inhibitors over a median follow-up period of 67.1 months. After adjusting confounding factors, the driving distance to the hospital per 10-km increase (hazard ratio [HR]=1.09, p=0.017) and the driving distance to hospital ≧16 km (HR=1.9, p=0.001) were significantly associated with a higher risk of TNF-α inhibitor discontinuation. Neither the driving time nor the public transit time to the hospital was significantly associated with TNF-α inhibitor persistence. Conclusion: Longer driving distances significantly increased the risk of treatment discontinuation, highlighting the need for healthcare systems to address these barriers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.